| Author: | ISBN: | 9783319637570 | |
| Publisher: | Springer International Publishing | Publication: | November 3, 2017 |
| Imprint: | Springer | Language: | English |
| Author: | |
| ISBN: | 9783319637570 |
| Publisher: | Springer International Publishing |
| Publication: | November 3, 2017 |
| Imprint: | Springer |
| Language: | English |
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
